| 1 |
34881519 | Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer. | 2022 Feb |
1 |
| 2 |
34036692 | Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. | 2021 Aug |
1 |
| 3 |
34234236 | SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy. | 2021 Jul 7 |
1 |
| 4 |
31669591 | Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. | 2020 Feb |
4 |
| 5 |
32376116 | Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival. | 2020 Sep |
1 |
| 6 |
32411590 | Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer. | 2020 |
1 |
| 7 |
30778772 | The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. | 2019 Feb 18 |
2 |
| 8 |
31454018 | Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. | 2019 Aug 27 |
1 |
| 9 |
29808239 | Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy. | 2018 May 28 |
1 |
| 10 |
30586539 | The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. | 2018 Oct |
2 |
| 11 |
28369553 | Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. | 2017 Jul 1 |
1 |
| 12 |
28529902 | Current state of immunotherapy for non-small cell lung cancer. | 2017 Apr |
2 |
| 13 |
29123433 | Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan. | 2017 |
1 |
| 14 |
29234489 | Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer. | 2017 Sep |
1 |
| 15 |
26650486 | The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. | 2016 Sep |
1 |
| 16 |
27623999 | Novel immunotherapy in the treatment of advanced non-small cell lung cancer. | 2016 Dec |
1 |
| 17 |
25266653 | C-MET inhibitors in the treatment of lung cancer. | 2014 Dec |
1 |
| 18 |
22887466 | Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. | 2013 Jan |
2 |
| 19 |
23277484 | Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. | 2013 May |
1 |
| 20 |
23841470 | The impact of genomic changes on treatment of lung cancer. | 2013 Oct 1 |
2 |
| 21 |
22771825 | Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. | 2012 Nov |
5 |
| 22 |
19667264 | Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. | 2009 Sep 10 |
1 |